Latest News and Press Releases

Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...

Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID studyUp to 110 COVID-19 patients to participate in...

Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trialsTACTI-002 study expanded in lung cancerNew phase II trial in head and neck cancer announcedEOC...

Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...

Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC)Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients startedFurther interim data...

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...

Sydney, AUSTRALIA, Dec. 16, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...

Efti clinical trial status updatesExcellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. ...

New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy,...

First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune...